Clinical consensus and progress of prophylactic cranial irradiation

doi:10.3760/cma.j.issn.1673422X.2017.03.015

Abstract

Abstract: Prophylactic cranial irradiation is an effective means of dealing with brain metastasis of cancer, which can reduce the incidence of brain metastasis by killing the micrometastasis and then improve the prognosis. The effectiveness has been verified in small cell lung cancer, but the application is still in the exploration in nonsmall cell lung cancer （NSCLC） and breast cancer. Prophylactic cranial irradiation is expected to become the conventional treatment for patients with NSCLC of ⅢAN2 stage after operation and adjuvant chemotherapy or breast cancer of epithelial growth factor receptorpositive after receiving trastuzumab.

Key words: Cranial irradiation, Lung neoplasms, Breast neoplasms

Liu Yandong, Zhou Juying. Clinical consensus and progress of prophylactic cranial irradiation[J]. Journal of International Oncology, 2017, 44(3): 217-220.

References

［1］ Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with smallcell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group［J ］. N Engl J Med, 1999, 341(7): 476-484. DOI: 10.1056/NEJM199908123410703. ［2］ Schild SE, Foster NR, Meyers JP, et al. Prophylactic cranial irradiation in smallcell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis［J］. Ann Oncol, 2012, 23(11): 2919 -2924. DOI:10.1093/annonc/mds123. ［3］ Zhang W, Jiang W, Luan L, et al. Prophylactic cranial irradiation for patients with smallcell lung cancer: a systematic review of the literature with metaanalysis［J］. BMC Cancer, 2014, 14: 793. DOI: 10.1186/1471240714793. ［4］ Rule WG, Foster NR, Meyers JP, et al. Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis［J］. J Geriatr Oncol, 2015, 6(2): 119-126. DOI:10.1016/j.jgo.2014.11.002. ［5］ Le Péchoux C, Dunant A, Senan S, et al. Standarddose versus higher dose prophylactic cranial irradiation (PCI) in patients with limitedstage smallcell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 9901, EORTC 2200308004, RTOG 0212, and IFCT 9901): a randomised clinical trial［J］. Lancet Oncol, 2009, 10(5): 467-474. DOI: 10.1016/S14702045(09)701019. ［6］ Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase Ⅱrandomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limiteddisease smallcell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(1): 7784. DOI: 10.1016/j.ijrobp.2010.05.013. ［7］ Sun A, Bae K, Gore EM, et al. Phase Ⅲ trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non smallcell lung cancer: neurocognitive and qualityoflife analysis［J ］. J Clin Oncol, 2011, 29(3): 279-286. DOI: 10.1200/JCO.2010.29.6053. ［8］ Won YW, Joo J, Yun T, et al. A nomogram to predict brain metastasis as the first relapse in curatively resected nonsmall cell lung cancer patients［J］. Lung Cancer, 2015, 88(2): 201-207. DOI: 10.1016/j.lungcan.2015.02.006. ［9］ Zhang F, Zheng W, Ying L, et al. A nomogram to predict brain metastases of resected nonsmall cell lung cancer patients［J］. Ann Surg Oncol, 2016, 23(9): 30333039. DOI: 10.1245/s1043401652063. ［10］ Lee DS, Kim SJ, Kang JH, et al. Serum carcinoembryonic antigen levels and the risk of wholebody metastatic potential in advanced nonsmall cell lung cancer［J］. J Cancer, 2014, 5(8): 663-669. DOI: 10.7150/jca.9871. ［11］ Horinouchi H, Sekine I, Sumi M, et al. Brain metastases after definitive concurrent chemoradiotherapy in patients with stage Ⅲ lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor［ J］. Cancer Sci, 2012, 103(4): 756-759. DOI: 10.1111/j.13497006201202217.x. ［12］ Hubbs JL, Boyd JA, Hollis D, et al. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer［J］. Cancer, 2010, 116(21): 5038-5046. DOI: 10.1002/cncr.25254. ［13］ Gore EM, Bae K, Wong SJ, et al. Phase Ⅲ comparison of prophylactic cranial irradiation versus observation in patients with locally advanced nonsmallcell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214［J］. J Clin Oncol, 2011, 29(3): 272-278. DOI: 10.1200/JCO.2010.29.1609. ［14］ Xie SS, Li M, Zhou CC, et al. Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with nonsmall cell lung cancer: a systematic review and metaanalysis［J］. PLoS One, 2014, 9(7): e103431. DOI: 10.1371/journal.pone.0103431. ［15］ Li N, Zeng ZF, Wang SY, et al. Randomized phase Ⅲ trial of prophylactic cranial irradiation versus observation in patients with fully resected stage ⅢAN2 nonsmallcell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy［J］. Ann Oncol, 2015, 26(3): 504-509. DOI: 10.1093/annonc/mdu567. ［16］ Niwińska A. Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment［J］. Clin Exp Metastasis, 2016, 33(7): 677-685. DOI: 10.1007/s1058501698021. ［17］ Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases［J］. Cancer, 2006, 107(4): 696-704. DOI: 10.1002/cncr.22041. ［18］ Graesslin O, Abdulkarim BS, Coutant C, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer［J］. J Clin Oncol, 2010, 28(12): 2032-2037. DOI: 10.1200/JCO.2009.24.6314. ［19］ HedayatizadenOmran A, Rafiei A, AlizadenNavaei R, et al. Role of HER2 in brain metastasis of breast cancer: a systematic review and metaanalysis［J］. Asian Pac J Cancer Prev, 2015, 16(4): 1431-1434. ［20］ Canney P, Murray E, DixonHughes J, et al. A prospective randomised phase Ⅲ clinical trial testing the role of prophylactic cranial radiotherapy in patients treated with trastuzumab for metastatic breast canceranglo celtic Ⅶ［J］. Clin Oncol (R Coll Radiol), 2015, 27 (8): 460-464. DOI: 10.1016/j.clon.2015.04.033.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[7]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[8]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[9]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[10]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[11]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[12]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.